The loss of efficacy of pembrolizumab is due to decreased expression of MHC molecules on tumor cells, as well as an increased immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells. The gene discussed is HLA-C; the disease is neoplasm.